ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Targets and incidences of hand-foot skin reaction caused by tyrosine kinase inhibitors

Targets and incidences of hand-foot skin reaction caused by tyrosine kinase inhibitors
TKI Targets Incidence of all-grade HFSR (%) Incidence of high-grade HFSR (%)
Axitinib[1] VEGFR-1, 2, and 3 29.2 9.6
Cabozantinib[2,3] VEGFR-2, c-MET, RET, c-KIT, FLT3, Tie-2 35.3 9.5
Lenvatinib[4] VEGFR-1, 2, and 3; FGFR-1, 2, 3, and 4; PDGFR-alpha; RET; KIT 65.2 8.7
Pazopanib[5] RAF, VEGFR-2 and 3, PDGFR-beta, c-KIT, FLT3, RET 4.5 1.8
Regorafenib[6] VEGFR-1, 2, and 3; Tie-2; FGFR-1; PDGFR-alpha and beta; c-KIT; RET; RAF; p38 MAPK 60.5 20.4
Sorafenib[7] VEGFR-2 and 3, PDGFR, A-RAF, B-RAF, C-RAF, FLT3 33.8 8.9
Sunitinib[8] VEGFR-2, PDGFR, c-KIT, FLT3 18.9 5.5
Ripretinib[9] KIT, PDGFR-alpha 21.0 0
TKI: tyrosine kinase inhibitor; HFSR: hand-foot skin reaction; VEGFR: vascular endothelial growth factor receptor; c-MET: cellular mesenchymal to epithelial transition factor; RET: rearranged during transfection; c-KIT: mast/stem cell growth factor; FLT3: FMS-like tyrosine kinase 3; Tie-2: tyrosine-protein kinase receptor; FGFR: fibroblast growth factor receptor; PDGFR: platelet-derived growth factor receptor; RAF: rapidly accelerated fibrosarcoma; MAPK: mitogen-activated protein kinase.
References:
  1. Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2013; 31:787.
  2. Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol 2016; 41:8.
  3. Zuo RC, Apolo AB, DiGiovanna JJ, et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol 2015; 151:170.
  4. Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017; 52:512.
  5. Balagula Y, Wu S, Su X, et al. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2012; 30:1773.
  6. Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 2013; 31:1078.
  7. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008; 47:176.
  8. Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009; 7:11.
  9. Zalcberg JR. Ripretinib for the treatment of advanced gastrointestinal stromal tumor. Therap Adv Gastroenterol 2021; 14:17562848211008177.
Graphic 109105 Version 3.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟